Brief: Hyloris Pharmaceuticals Says It Obtains Exclusive License Rights In Europe & Turkey From Arbormed For Its Wilson's Disease Therapy
30/12/2025 17:18
Dec 30 (Reuters) - Hyloris Pharmaceuticals SA HYL.BR: HYLORIS PHARMACEUTICALS: OBTAINS EXCLUSIVE LICENSE RIGHTS IN EUROPE & TURKEY FROM ARBORMED FOR ITS WILSON'S DISEASE THERAPY, INCLUDING PAYMENT OF USD 2 MILLION Source text: [ID:] Further company coverage: HYL.BR ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hyloris Pharmaceuticals SA
See all newsBrief: Hyloris Pharmaceuticals Says It Obtains Exclusive License Rights In Europe & Turkey From Arbormed For Its Wilson's Disease Therapy
Brief: Hyloris Announces Partnership With Rosemont Pharmaceuticals For Atomoxetine Oral Solution In The U.S.
Brief: Hyloris Announces Positive Study Results For Dofetilide IV
Brief: Hyloris Pharmaceuticals SA Says HY 2024 Revenues (Royalties And Milestones) Increased To EUR 4,2 Million
Brief: Euronext Announces Quarterly Review Of BEL Family Indices